Page 34 - ஜப்பான் அமைச்சகம் ஆஃப் ஆரோக்கியம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Press release content from PR Newswire. The AP news staff was not involved in its creation. Astellas Submits New Drug Application for Enfortumab Vedotin in Japan March 11, 2021 GMT Astellas is a pharmaceutical company dedicated to improving the health of people around the world. (PRNewsFoto/Astellas Pharma Inc.) Astellas is a pharmaceutical company dedicated to improving the health of people around the world. (PRNewsFoto/Astellas Pharma Inc.) TOKYO, March 11, 2021 /PRNewswire/ Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced the submission of a New Drug Application (NDA) to Japan’s Ministry of Health, Labour and Welfare (MHLW) for enfortumab vedotin for the treatment of patients with locally advanced or metastatic urothelial cancer that has progressed after anti-cancer medication. If approved, enfortumab vedotin would be the first antibody-drug conjugate (ADC) available in Japan for people living with this form of uro

United statesAl iskandariyahMinistry of healthAl qahirahKenji yasukawaAndrew krivoshikEnfortumab vedotinAmerican society of clinical oncologyValue healthCancer information serviceSeagen incAstellas pharma incJapan ministry of healthPrnewswire astellas pharma incNew drug applicationSenior vice president